Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study.

IF 2.3 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2026-10-01 Epub Date: 2026-06-18 DOI:10.1007/s00595-026-03375-0

Masatsugu Hamaji, Ryo Miyata, Jiro Takeuchi, Naoki Ozu, Takuya Kohama, Ryota Sumitomo, Mamoru Takahashi, Takehisa Fukada, Megumi Kobayashi, Yosuke Kumaya, Toyofumi Fengshi Chen-Yoshikawa

{"title":"Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study.","authors":"Masatsugu Hamaji, Ryo Miyata, Jiro Takeuchi, Naoki Ozu, Takuya Kohama, Ryota Sumitomo, Mamoru Takahashi, Takehisa Fukada, Megumi Kobayashi, Yosuke Kumaya, Toyofumi Fengshi Chen-Yoshikawa","doi":"10.1007/s00595-026-03375-0","DOIUrl":null,"url":null,"abstract":"Purpose: The current guidelines recommend cisplatin-based adjuvant chemotherapy for patients with completely resected stage II-III non-small cell lung cancer (NSCLC). Carboplatin-based chemotherapy is occasionally selected, although there is limited evidence of its long-term outcomes. We conducted this study to compare the long-term outcomes of cisplatin- based chemotherapy with those of carboplatin-based chemotherapy.Methods: A retrospective chart review was performed to identify patients aged ≥ 18 years with performance status 0-1, complete resection, and pathological stage II-IIIA NSCLC (7th edition) between 2014 and 2016 in our multi-institutional database. Patients were classified into two groups: the cisplatin-based adjuvant chemotherapy group and the carboplatin-based adjuvant chemotherapy group. To adjust for baseline differences, inverse probability of treatment weighting (IPTW) based on propensity scores was applied. The primary outcome was recurrence-free survival (RFS) and the secondary outcomes were cancer-specific survival (CSS) and overall survival (OS).Results: A total 342 patients were included, of whom 195 received cisplatin-based adjuvant chemotherapy and 147 received carboplatin-based chemotherapy. After IPTW adjustment, the hazard ratios for RFS, CSS, and OS were 1.10 (95% confidence interval [CI]: 0.82-1.49, p = 0.526), 1.11 (95% CI: 0.68-1.82, p = 0.675), and 1.46 (95% CI: 0.96-2.22, p = 0.08), respectively.Conclusions: Carboplatin-based adjuvant chemotherapy may be considered for selected patients deemed unfit to receive cisplatin.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"2370-2377"},"PeriodicalIF":2.3000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-026-03375-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The current guidelines recommend cisplatin-based adjuvant chemotherapy for patients with completely resected stage II-III non-small cell lung cancer (NSCLC). Carboplatin-based chemotherapy is occasionally selected, although there is limited evidence of its long-term outcomes. We conducted this study to compare the long-term outcomes of cisplatin- based chemotherapy with those of carboplatin-based chemotherapy.

Methods: A retrospective chart review was performed to identify patients aged ≥ 18 years with performance status 0-1, complete resection, and pathological stage II-IIIA NSCLC (7th edition) between 2014 and 2016 in our multi-institutional database. Patients were classified into two groups: the cisplatin-based adjuvant chemotherapy group and the carboplatin-based adjuvant chemotherapy group. To adjust for baseline differences, inverse probability of treatment weighting (IPTW) based on propensity scores was applied. The primary outcome was recurrence-free survival (RFS) and the secondary outcomes were cancer-specific survival (CSS) and overall survival (OS).

Results: A total 342 patients were included, of whom 195 received cisplatin-based adjuvant chemotherapy and 147 received carboplatin-based chemotherapy. After IPTW adjustment, the hazard ratios for RFS, CSS, and OS were 1.10 (95% confidence interval [CI]: 0.82-1.49, p = 0.526), 1.11 (95% CI: 0.68-1.82, p = 0.675), and 1.46 (95% CI: 0.96-2.22, p = 0.08), respectively.

Conclusions: Carboplatin-based adjuvant chemotherapy may be considered for selected patients deemed unfit to receive cisplatin.

查看原文本刊更多论文

顺铂与卡铂作为完全切除非小细胞肺癌的辅助化疗：一项多中心回顾性队列研究

目的：目前的指南推荐顺铂为基础的辅助化疗用于完全切除的II-III期非小细胞肺癌（NSCLC）患者。偶尔会选择以卡铂为基础的化疗，尽管关于其长期疗效的证据有限。我们进行这项研究是为了比较以顺铂为基础的化疗和以卡铂为基础的化疗的长期结果。方法：回顾性分析2014 - 2016年多机构数据库中年龄≥18岁、表现状态0-1、完全切除、病理分期II-IIIA期NSCLC（第7版）的患者。患者分为两组：顺铂辅助化疗组和卡铂辅助化疗组。为了调整基线差异，应用基于倾向得分的治疗加权逆概率（IPTW）。主要终点为无复发生存期（RFS），次要终点为癌症特异性生存期（CSS）和总生存期（OS）。结果：共纳入342例患者，其中以顺铂为主的辅助化疗195例，以卡铂为主的化疗147例。经IPTW校正后，RFS、CSS和OS的风险比分别为1.10（95%可信区间[CI]: 0.82 ~ 1.49, p = 0.526）、1.11 （95% CI: 0.68 ~ 1.82, p = 0.675）和1.46 （95% CI: 0.96 ~ 2.22, p = 0.08）。结论：对于不适合接受顺铂治疗的患者，可考虑卡铂辅助化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.